Oryzon Genomics S.A. (ORY.MC)

EUR 2.67

(1.52%)

EBITDA Summary of Oryzon Genomics S.A.

  • Oryzon Genomics S.A.'s latest annual EBITDA in 2023 was -4.43 Million EUR , up 16.02% from previous year.
  • Oryzon Genomics S.A.'s latest quarterly EBITDA in 2024 Q3 was -2.79 Million EUR , down -428.52% from previous quarter.
  • Oryzon Genomics S.A. reported an annual EBITDA of -5.35 Million EUR in 2022, up 22.82% from previous year.
  • Oryzon Genomics S.A. reported an annual EBITDA of -6.88 Million EUR in 2021, down -58.08% from previous year.
  • Oryzon Genomics S.A. reported a quarterly EBITDA of -2.79 Million EUR for 2024 Q3, down -428.52% from previous quarter.
  • Oryzon Genomics S.A. reported a quarterly EBITDA of -3.24 Million USD for 2024 Q1, down -167.36% from previous quarter.

Annual EBITDA Chart of Oryzon Genomics S.A. (2023 - 2019)

Created with Highcharts 11.1.0YearsEBITDA20192019.520202020.520212021.520222022.52023-8000000 EUR-7000000 EUR-6000000 EUR-5000000 EUR-4000000 EUR-3000000 EUR

Historical Annual EBITDA of Oryzon Genomics S.A. (2023 - 2019)

Year EBITDA EBITDA Growth
2023 -4.43 Million EUR 16.02%
2022 -5.35 Million EUR 22.82%
2021 -6.88 Million EUR -58.08%
2020 -4.16 Million EUR 60.57%
2019 -3.69 Million EUR 0.0%

Peer EBITDA Comparison of Oryzon Genomics S.A.

Name EBITDA EBITDA Difference
Atrys Health, S.A. 31.91 Million EUR 113.892%
Biotechnologies Assets SA 5.09 Million EUR 186.947%
Pharma Mar, S.A. 4.54 Million EUR 197.458%
Laboratorios Farmaceuticos Rovi, S.A. 245.81 Million EUR 101.804%